Wolverine Legal Status, FDA 503A Category, and Compounding Access

Where Wolverine legal status stands today

The Wolverine legal status question turns on the FDA 503A category of its two constituents, and the near-term story is one of momentum. Access to compounded BPC-157 TB-500 is under active FDA review and may expand in 2026 — both constituents are on the published agenda of a Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, where they are listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[10]. That is a scheduled evaluation, a real step in the pathway — not a listing decision, not a reclassification, and not an outcome with a date.

As the record stands today, both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" are in FDA's Category 2 for 503A compounding, effective with the September 29, 2023 update to FDA's list of nominated bulk drug substances ^[11]. Category 2 means FDA identified each as a bulk drug substance that may present significant safety risks — citing concerns including potential immunogenicity for certain routes of administration and, for BPC-157, complexities with peptide-related impurities and active-ingredient characterization ^[11]. Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding, so compounding-pharmacy access to these ingredients is currently restricted ^[11][12]. Neither constituent is an FDA-approved drug, and the blend has no approved indication ^[11].

This is general information about the regulatory landscape, not medical or legal advice.

Why "503A Category 2" matters

Under the U.S. Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities and licensed physicians, generally pursuant to a valid prescription for an individual patient; Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[12]. A compounder may use a bulk drug substance — an active ingredient used as a starting material rather than a finished approved drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[12].

FDA's interim policy sorted nominated substances into categories. Category 1 substances may be eligible for the bulks list and are covered by FDA's enforcement-discretion policy while evaluation continues; Category 2 substances were identified as raising significant safety risks and are not covered by that policy, meaning FDA stated it would consider taking action against a compounder for compounding with them ^[12]. On January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories; substances already in Category 1 may continue within the interim enforcement-discretion policy, while FDA has stated Category 2 substances are not afforded that discretion even if nominations are updated ^[12]. Both Wolverine constituents sit in Category 2 today ^[11].

Both constituents are on the FDA's July 2026 review agenda

There is no component carve-out in the Wolverine blend's regulatory status: both BPC-157 and TB-500 are currently Category 2, and both fall under the same scheduled review. FDA's public calendar lists BPC-157 (the entries "BPC-157 (free base)" / "BPC-157 acetate") and TB-500 ("TB-500 (free base)" / "TB-500 acetate") among the bulk drug substances "being considered for inclusion on the 503A Bulks List" at the July 23-24, 2026 PCAC meeting ^[10][11]. Inclusion on a final bulks list is decided by FDA rulemaking informed by PCAC; being discussed by the committee is a step in evaluation, not a final listing decision, and no outcome should be assumed or dated ^[12][10].

What this means for the blend: the same single scheduled review covers both legs of the pairing. A reader watching the access picture for BPC-157 TB-500 is watching one meeting and two agenda entries — and watching a process that is, by FDA's own calendar, ongoing rather than resolved ^[10].

How legally compounded peptide access works

Separately from any future decision, the lawful pathway for a compounded medication in the U.S. is well-defined and worth understanding in general terms. A legally compounded preparation is made only after an individual patient is evaluated by an appropriately licensed prescriber who determines that a compounded preparation is clinically appropriate, and who then issues a valid, patient-specific prescription ^[12]. The preparation is dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility ^[12].

Telehealth can serve as the front-end channel for that prescriber evaluation, in person or through a compliant telehealth encounter — but it is a route to a licensed-prescriber consultation, not a separate legal status ^[12]. Telehealth does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription ^[12]. And the ingredient-eligibility caveat governs the whole pathway: a compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules, so an ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[12]. That caveat is exactly what applies to both Wolverine constituents today ^[11]. This page names no specific pharmacy, clinic, telehealth provider or vendor, gives no dosing, and describes the lawful framework only — not any way to obtain a restricted substance outside it.

Access and safety FAQs

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use and the blend has no approved indication ^[11]. Both are prohibited by WADA — BPC-157 under the S0 non-approved-substances category and TB-500 / Thymosin Beta-4 under prohibited peptide and tissue-repair categories ^[5]. As it stands today, FDA placed both constituents in Category 2 for 503A compounding (effective September 29, 2023), so they are not within FDA's enforcement-discretion policy pending further evaluation ^[11].

Can you get BPC-157 from a compounding pharmacy?

As the record stands today, BPC-157 is in FDA's Category 2 for 503A compounding (effective September 29, 2023), which means it is not within FDA's enforcement-discretion policy and access through that route is currently restricted ^[11]. BPC-157 is on the FDA's July 23-24, 2026 PCAC agenda as a substance being considered for inclusion on the 503A bulks list — a scheduled review, not a decision ^[10].

What is the FDA 503A status of Wolverine?

Both constituents are FDA 503A Category 2 today — BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — effective with the September 29, 2023 list update ^[11]. Both are on the July 23-24, 2026 PCAC agenda as candidates for the 503A bulks list, under active review with no outcome decided ^[10]. Neither constituent nor the blend is an approved medicine ^[11].